Related Experiment Video

Updated: Jun 21, 2025

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.3K

Metabolic vulnerabilities in cancer: A new therapeutic strategy

Mohamed El-Tanani1, Syed Arman Rabbani1, Yahia El-Tanani2

  • 1RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.

Critical Reviews in Oncology/Hematology
|July 8, 2024
PubMed

Insights

Targeting cancer metabolism with glycolysis and glutaminase inhibitors offers new therapeutic avenues. Combining these strategies with personalized medicine and lifestyle changes can improve patient outcomes in oncology.

Area of Science:

  • Oncology
  • Cancer Biology
  • Metabolic Pathways

Background:

  • Cancer cells exhibit unique metabolic reprogramming essential for tumor growth and survival.
  • Metabolic vulnerabilities present a promising target for novel cancer therapeutics.
  • Dysregulated metabolism is a hallmark of cancer, driving proliferation and resistance.

Purpose of the Study:

  • To review the therapeutic potential of targeting cancer metabolism.
  • To discuss the role of glycolysis and glutaminase inhibitors in disrupting cancer cell metabolism.
  • To explore strategies for enhancing the efficacy of metabolic targeting in cancer therapy.

Main Methods:

  • Review of current literature on cancer metabolism and therapeutic interventions.
  • Analysis of glycolysis and glutaminase inhibitors' mechanisms of action.
  • Discussion of challenges like tumor heterogeneity and adaptive resistance.

Main Results:

  • Glycolysis and glutaminase inhibitors show significant potential in disrupting cancer metabolism.
  • Personalized medicine and predictive biomarkers can enhance treatment efficacy.
  • Integrating diet and lifestyle changes offers a holistic approach to improving therapy outcomes.

Conclusions:

  • Exploiting metabolic vulnerabilities represents a paradigm shift in oncology.
  • Metabolic targeting is poised to become a cornerstone of personalized cancer therapy.
  • Tailored, safer treatments through metabolic targeting promise to transform patient care.
Keywords:
Adaptive resistanceCancer metabolismGlutaminase inhibitorsGlycolysis inhibitorsMetabolic reprogrammingPersonalized medicinePredictive biomarkersTumor heterogeneity

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.3K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
12.8K